Overview |
bs-9377R |
EDPF1 Polyclonal Antibody |
WB, IHC-P, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human MMS2/EDPF1 |
65-145/145 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
7336 |
1 alpha 25 dihydroxyvitamin D3 inducible; DDVit 1; DDVIT1; EDAF-1; EDAF1; EDPF-1; EDPF1; Enterocyte dferentiation associated factor EDAF 1; Enterocyte dferentiation promoting factor; Enterocyte dferentiation-associated factor 1; Enterocyte dferentiation-promoting factor 1; Methyl methanesulfonate sensitive 2; MMS 2; MMS2; MMS2 homolog; UB2V2_HUMAN; UBE2V 2; UBE2V2; Ubiquitin conjugating enzyme E2 variant 2; Ubiquitin conjugating enzyme E2v2; Ubiquitin-conjugating enzyme E2 variant 2; UEV 2; UEV2; Vitamin D3 inducible protein; Vitamin D3-inducible protein. |
Has no ubiquitin ligase activity on its own. The UBE2V2/UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through 'Lys-63'. This type of poly-ubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(IHC-P) |
1:50-200 |